histogenics
-
Hospitals
Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway
WALTHAM, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative…
Read More » -
Biologics
Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative…
Read More » -
Hospitals
Histogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
WALTHAM, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative…
Read More » -
Biologics
Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart® in Patients With Knee Cartilage Damage
WALTHAM, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative…
Read More » -
Financial
Histogenics Corporation Announces Second Quarter 2018 Financial and Operating Results
WALTHAM, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative…
Read More » -
Biologics
Histogenics Agreement With Japan Pharmaceuticals and Medical Devices Agency and Regulatory Pathway for NeoCart®
WALTHAM, Mass., May 08, 2017 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Biologics
Histogenics Announces Publication of Biomechanical and Structural Data From Human Engineered Cartilage Testing
WALTHAM, Mass., March 09, 2017 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Biologics
Histogenics Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (HSGX), a regenerative medicine company focused on developing and…
Read More » -
Sports Medicine
Histogenics Announces Publication of MRI Data From NeoCart® Phase 1 and Phase 2 Clinical Trials in the American Journal of Sports Medicine
WALTHAM, Mass., Jan. 11, 2017 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (HSGX), a regenerative medicine company focused on developing and…
Read More » -
Financial
Histogenics Corporation Announces Third Quarter 2016 Financial and Operating Results
WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Biologics
Histogenics Corporation Announces Addition of Dr. Lawrence Bonassar of Cornell University to Its Scientific Advisory Board
WALTHAM, Mass., Oct. 06, 2016 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the…
Read More » -
Financial
Histogenics Corporation Announces $30.0 Million Private Placement
WALTHAM, Mass., Sept. 16, 2016 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the…
Read More » -
Financial
Histogenics Corporation Announces Second Quarter 2016 Financial and Operating Results
WALTHAM, Mass., Aug. 11, 2016 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Financial
Histogenics Corporation Acquires NeoCart® Development and Commercialization Rights for Japanese Market
WALTHAM, Mass., May 10, 2016 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Financial
Analysts Anticipate Histogenics Corp to Announce ($0.47) Earnings Per Share (NASDAQ:HSGX)
By Jennifer Langley Histogenics Corp (NASDAQ:HSGX) has received an average broker rating score of 1.50 (Buy) from the two brokers…
Read More »